8-K current report · filed Oct 29, 2026

Stoke Therapeutics, Inc. (STOK) 8-K Current Report: October 29, 2026

Item 2.02Item EX-99.1STOK overview

Short answer

Stoke Therapeutics, Inc. (STOK) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.

Stoke Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Investors should review the accompanying press release for reported financial figures and operating updates

Item EX-99.1 · Exhibit EX-99.1

  • Phase 3 EMPEROR enrollment complete at 162 patients, with data readout anticipated Q3 2027 and U.S. NDA planned H2 2027
  • Approximately 110 patients reached Week 28, the primary seizure endpoint, while no patients have discontinued treatment
  • FDA alignment supports four-domain Vineland-3 cognition and behavior analysis, potentially strengthening the regulatory package
  • Cash, equivalents and marketable securities $358.8M, expected to fund operations into early 2028
  • Q3 net loss widened to $73.6M from $38.3M, with R&D rising to $59.8M and SG&A to $28.7M for clinical and launch preparation

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Stoke Therapeutics, Inc. 8-K filings

Get the next STOK 8-K as it lands

Follow STOK for push alerts, or ask the research agent what this filing means.